{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T20:57:51Z","timestamp":1768424271265,"version":"3.49.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T00:00:00Z","timestamp":1624838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T00:00:00Z","timestamp":1624838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010336","name":"Fundaci\u00f3 Privada Daniel Bravo Andreu","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We assessed the duration and baseline determinants of antibody responses to SARS-CoV-2 spike antigens and the occurrence of reinfections in a prospective cohort of 173 Spanish primary health care worker patients followed initially for 9 months and subsequently up to 12.5 months after COVID-19 symptoms onset. Seropositivity to SARS-CoV-2 spike and receptor-binding domain antigens up to 149\u2013270 days was 92.49% (90.17% IgG, 76.3% IgA, 60.69% IgM). In a subset of 64 health care workers who had not yet been vaccinated by April 2021, seropositivity was 96.88% (95.31% IgG, 82.81% IgA) up to 322\u2013379 days post symptoms onset. Four suspected reinfections were detected by passive case detection, two among seronegative individuals (5 and 7 months after the first episode), and one low antibody responder. Antibody levels significantly correlated with fever, hospitalization, anosmia\/hypogeusia, allergies, smoking, and occupation. Stable sustainment of IgG responses raises hope for long-lasting COVID-19 vaccine immunity.<\/jats:p>","DOI":"10.1186\/s12916-021-02032-2","type":"journal-article","created":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T15:03:05Z","timestamp":1624892585000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Persistence and baseline determinants of seropositivity and reinfection rates in health care workers up to 12.5 months after COVID-19"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6751-4060","authenticated-orcid":false,"given":"Carlota","family":"Doba\u00f1o","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Ram\u00edrez-Morros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selena","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep","family":"Vidal-Alaball","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gemma","family":"Ruiz-Olalla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roc\u00edo","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Cascant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Parras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Rodrigo Melero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pau","family":"Serra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Carolis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pere","family":"Santamaria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Forcada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacobo","family":"Mendioroz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Aguilar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gemma","family":"Moncunill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Ruiz-Comellas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,28]]},"reference":[{"key":"2032_CR1","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1126\/science.abd7728","volume":"370","author":"A Wajnberg","year":"2020","unstructured":"Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M, et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science (80- ). 2020;370:1227\u201330.","journal-title":"Science (80- )"},{"key":"2032_CR2","doi-asserted-by":"publisher","first-page":"100228","DOI":"10.1016\/j.xcrm.2021.100228","volume":"2","author":"A Abayasingam","year":"2021","unstructured":"Abayasingam A, Balachandran H, Agapiou D, Hammoud M, Rodrigo C, Keoshkerian E, et al. Long-term persistence of RBD+ memory B cells encoding neutralizing antibodies in SARS-CoV-2 infection. Cell Reports Med. 2021;2:100228.","journal-title":"Cell Reports Med."},{"key":"2032_CR3","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.cell.2021.01.050","volume":"184","author":"A Sokal","year":"2021","unstructured":"Sokal A, Chappert P, Barba-Spaeth G, Roeser A, Fourati S, Azzaoui I, et al. Maturation and persistence of the anti-SARS-CoV-2 memory B cell response. Cell. 2021;184:1201\u20131213.e14.","journal-title":"Cell"},{"key":"2032_CR4","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.medj.2021.02.001","volume":"2","author":"N Sherina","year":"2021","unstructured":"Sherina N, Piralla A, Du L, Wan H, Kumagai-Braesch M, Andr\u00e9ll J, et al. Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6\u20138 months after the infection. Med. 2021;2:281\u2013295.e4.","journal-title":"Med"},{"key":"2032_CR5","doi-asserted-by":"crossref","unstructured":"Ortega N, Ribes M, Vidal M, Rubio R, Aguilar R, Williams S, et al. Seven-month kinetics of SARS-CoV-2 antibodies and protective role of pre- existing antibodies to seasonal human coronaviruses on COVID-19. medRxiv. 2021:2021.02.22.21252150 2021.02.22.21252150v2.","DOI":"10.1101\/2021.02.22.21252150"},{"key":"2032_CR6","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","volume":"586","author":"F Krammer","year":"2020","unstructured":"Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020;586:516\u201327. https:\/\/doi.org\/10.1038\/s41586-020-2798-3.","journal-title":"Nature."},{"key":"2032_CR7","doi-asserted-by":"publisher","unstructured":"Klingler J, Weiss S, Itri V, Liu X, Oguntuyo KY, Stevens C, Ikegame S, Hung CT, Enyindah-Asonye G, Amanat F, Baine I, Arinsburg S, Bandres JC, Kojic EM, Stoever J, Jurczyszak D, Bermudez-Gonzalez M, N\u00e1das A, Liu S, Lee B, Zolla-Pazner S, Hioe CE. Role of Immunoglobulin M and A Antibodies in the Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2. J Infect Dis. 2021;223(6):957\u201370. https:\/\/doi.org\/10.1093\/infdis\/jiaa784.","DOI":"10.1093\/infdis\/jiaa784"},{"key":"2032_CR8","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1038\/s41564-020-00813-8","volume":"5","author":"J Seow","year":"2020","unstructured":"Seow J, Graham C, Merrick B, Acors S, Pickering S, Steel KJA, et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat Microbiol. 2020;5:1598\u2013607. https:\/\/doi.org\/10.1038\/s41564-020-00813-8.","journal-title":"Nat Microbiol."},{"key":"2032_CR9","doi-asserted-by":"publisher","first-page":"eabf4063","DOI":"10.1126\/science.abf4063","volume":"371","author":"JM Dan","year":"2021","unstructured":"Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological memory to SARS-CoV-2 assessed for up to eight months after infection. Science (80- ). 2021;371:eabf4063.","journal-title":"Science (80- )"},{"key":"2032_CR10","doi-asserted-by":"publisher","first-page":"928","DOI":"10.3201\/eid2703.204543","volume":"27","author":"PG Choe","year":"2021","unstructured":"Choe PG, Kim KH, Kang CK, Suh HJ, Kang EK, Lee SY, et al. Antibody responses 8 months after asymptomatic or mild SARS-CoV-2 infection. Emerg Infect Dis. 2021;27:928\u201331. https:\/\/doi.org\/10.3201\/eid2703.204543.","journal-title":"Emerg Infect Dis."},{"key":"2032_CR11","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/S0140-6736(21)00238-5","volume":"397","author":"Z He","year":"2021","unstructured":"He Z, Ren L, Yang J, Guo L, Feng L, Ma C, et al. Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study. Lancet. 2021;397:1075\u201384. https:\/\/doi.org\/10.1016\/S0140-6736(21)00238-5.","journal-title":"Lancet."},{"key":"2032_CR12","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.immuni.2020.10.004","volume":"53","author":"TJ Ripperger","year":"2020","unstructured":"Ripperger TJ, Uhrlaub JL, Watanabe M, Wong R, Castaneda Y, Pizzato HA, et al. Orthogonal SARS-CoV-2 serological assays enable surveillance of low-prevalence communities and reveal durable humoral immunity. Immunity. 2020;53:925\u2013933.e4.","journal-title":"Immunity"},{"key":"2032_CR13","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1002\/jmv.26646","volume":"93","author":"C Liu","year":"2021","unstructured":"Liu C, Yu X, Gao C, Zhang L, Zhai H, Hu Y, et al. Characterization of antibody responses to SARS-CoV-2 in convalescent COVID-19 patients. J Med Virol. 2021;93:2227\u201333. https:\/\/doi.org\/10.1002\/jmv.26646.","journal-title":"J Med Virol."},{"key":"2032_CR14","doi-asserted-by":"crossref","unstructured":"Gaebler C, Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Tokuyama M, et al. Evolution of Antibody Immunity to SARS-CoV-2. bioRxiv. 2020:2020.11.03.367391.","DOI":"10.1101\/2020.11.03.367391"},{"key":"2032_CR15","doi-asserted-by":"publisher","unstructured":"Pradenas E, Trinit\u00e9 B, Urrea V, Marfil S, \u00c1vila-Nieto C, Rodr\u00edguez de la Concepci\u00f3n ML, Tarr\u00e9s-Freixas F, P\u00e9rez-Yanes S, Rovirosa C, Ainsua-Enrich E, Rodon J, Vergara-Alert J, Segal\u00e9s J, Guallar V, Valencia A, Izquierdo-Useros N, Paredes R, Mateu L, Chamorro A, Massanella M, Carrillo J, Clotet B, Blanco. Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes. J. Med (N Y). 2021;2(3):313\u201320.e4. https:\/\/doi.org\/10.1016\/j.medj.2021.01.005. Epub 2021 Jan 31.","DOI":"10.1016\/j.medj.2021.01.005"},{"key":"2032_CR16","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/j.cell.2020.10.051","volume":"183","author":"Y Chen","year":"2020","unstructured":"Chen Y, Zuiani A, Fischinger S, Mullur J, Atyeo C, Travers M, et al. Quick COVID-19 healers sustain anti-SARS-CoV-2 antibody production. Cell. 2020;183:1496\u20131507.e16. https:\/\/doi.org\/10.1016\/j.cell.2020.10.051.","journal-title":"Cell"},{"key":"2032_CR17","first-page":"e01731","volume":"59","author":"C Doba\u00f1o","year":"2020","unstructured":"Doba\u00f1o C, Vidal M, Santano R, Jim\u00e9nez A, Chi J, Barrios D, et al. Highly sensitive and specific multiplex antibody assays to quantify immunoglobulins M, A and G against SARS-CoV-2 antigens. J Clin Microbiol. 2020;59:e01731\u201320.","journal-title":"J Clin Microbiol."},{"key":"2032_CR18","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1093\/infdis\/jiaa696","volume":"223","author":"G Moncunill","year":"2021","unstructured":"Moncunill G, Mayor A, Santano R, Jim\u00e9nez A, Vidal M, Tortajada M, et al. SARS-CoV-2 seroprevalence and antibody kinetics among health care workers in a spanish hospital after 3 months of follow-up. J Infect Dis. 2021;223:62\u201371. https:\/\/doi.org\/10.1093\/infdis\/jiaa696.","journal-title":"J Infect Dis."},{"key":"2032_CR19","doi-asserted-by":"publisher","unstructured":"Hartley GE, Edwards ESJ, Aui PM, Varese N, Stojanovic S, McMahon J, et al. Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence. Sci Immunol. 2020;5. https:\/\/doi.org\/10.1126\/sciimmunol.abf8891.","DOI":"10.1126\/sciimmunol.abf8891"},{"key":"2032_CR20","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.jaci.2020.08.008","volume":"146","author":"JM Yang","year":"2020","unstructured":"Yang JM, Koh HY, Moon SY, Yoo IK, Ha EK, You S, et al. Allergic disorders and susceptibility to and severity of COVID-19: a nationwide cohort study. J Allergy Clin Immunol. 2020;146:790\u20138. https:\/\/doi.org\/10.1016\/j.jaci.2020.08.008.","journal-title":"J Allergy Clin Immunol."},{"key":"2032_CR21","doi-asserted-by":"publisher","first-page":"3989","DOI":"10.3390\/jcm9123989","volume":"9","author":"A Schaffner","year":"2020","unstructured":"Schaffner A, Risch L, Aeschbacher S, Risch C, Weber MC, Thiel SL, et al. Characterization of a pan-immunoglobulin assay quantifying antibodies directed against the receptor binding domain of the SARS-CoV-2 S1-subunit of the spike protein: a population-based study. J Clin Med. 2020;9:3989. https:\/\/doi.org\/10.3390\/jcm9123989.","journal-title":"J Clin Med."},{"key":"2032_CR22","doi-asserted-by":"publisher","unstructured":"Jonsdottir HR, Bielecki M, Siegrist D, Buehrer TW, Z\u00fcst R, Deuel JW. Titers of neutralizing antibodies against SARS-CoV-2 are independent of symptoms of non-severe COVID-19 in young adults. Viruses. 2021;13. https:\/\/doi.org\/10.3390\/v13020284.","DOI":"10.3390\/v13020284"},{"key":"2032_CR23","doi-asserted-by":"publisher","unstructured":"Lumley SF, O\u2019Donnell D, Stoesser NE, Matthews PC, Howarth A, Hatch SB, et al. Antibody status and incidence of SARS-CoV-2 infection in health care workers. N Engl J Med. 2021;384(6):533\u201340. https:\/\/doi.org\/10.1056\/NEJMoa2034545. Epub 2020 Dec 23.","DOI":"10.1056\/NEJMoa2034545"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-021-02032-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-021-02032-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-021-02032-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T19:49:46Z","timestamp":1672602586000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-021-02032-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,28]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2032"],"URL":"https:\/\/doi.org\/10.1186\/s12916-021-02032-2","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,28]]},"assertion":[{"value":"8 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the IRB <i>Comit\u00e8 \u00c8tic d'Investigaci\u00f3 Cl\u00ednica IDIAP Jordi Gol<\/i> (codes 20\/094-PCV and 20\/162-PCV), and written informed consent was obtained from participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"155"}}